Share this post on:

Tant 39UTRs. The primers for cloning the mutant 39-UTRs of MedChemExpress CASIN Cyclin D1 and Bcl-2 were as follows: Cyclin D1 binding site 1, sense, 59- TTT CTT ATT GCG CAC GTA CCG TTG ACT TCC AG-39 and antisense, 59- CTG GAA GTC AAC GGT ACG TGC GCA ATA AGA AA -39; Cyclin D1 binding site 2,sense, 59- CTT TCA CAT TGT TTG GAC CTA TTG GAG GAT CAG -39 and antisense, 59- CTG ATC CTC CAA TAG GTC CAA ACA ATG TGA AAG -39;Bcl-2, sense, 59- GGA ATA TCC AAT CCT GTC GAC CTA TCC TGC CAA-39 and antisense, 59- TTG GCA GGA TAG GTC GAC AGG ATT GGA TAT TCC-39. All constructs were confirmed by DNA sequencing. SCC-15 and CAL27 cells grown in a 48-well plate were co-transfected with 400 ng of either pcDNA3.0 or pcDNA3.0-miR-195, 40 ng of the firefly luciferase reporter plasmid including the 39-UTR of thetarget gene, and 4 ng of pRL-TK, a plasmid expressing rellina luciferase (Promega, Madison, WI)). After 24 h, the dual-luciferase reporter assay was performed 1326631 as reported [27].Western Blot AnalysisCells were lysed in RIPA lysis buffer (50 mM Tris/HCl, pH 8.0, 250 mM NaCl, 1 NP40, 0.5 (w/v) sodium deoxycholate, 0.1 sodium dodecylsulfate). Lysates were sonicated and centrifuged at 12,000 g/min at 4uC for 10 min. Aliquots (50 mg) of the protein extracts were subjected to 12 SDS polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane (Millipore, Billerica, MA). Membranes were incubated ?with primary antibodies at 4C overnight and washed extensively, followed by incubation with horseradish peroxidase-conjugated second antibodies (Zhongshan Goldenbridge, Beijing, China, 1:10,000 dilution) at room temperature for 1 h and detected with ECL kit (Applygen, Beijing, China). The primary antibodies, Cyclin D1 (Santa Cruz Biotechnology, Santa Cruz, CA), Bcl-2 (Cell Signaling Technology, Beverly, MA), and b-actin (Santa Cruz) were diluted 1:1,000 respectively.RNA OligoribonucleotideThe small interfering RNA (siRNA) targeting human Cyclin D1 and Bcl-2 transcripts and siRNA control were purchased from Integrated Biotech Solutions Company (Ibsbio, Shanghai, China). Sequence of these siRNAs were: Cyclin D1 siRNA, sense, 59-CAA GCU CAA GUG GAA CCU GTT-39, antisense, 59-CAG GUUMiR-195 Is a Prognostic Factor for TSCC PatientsCCA CUU GAG CUU GTT-39; Bcl-2 siRNA, sense, 59-GUG AAG UCA ACA UGC CUG CTT-39, antisense, 59-GCA GGC AUG UUG ACU UCA CTT-39; siRNA control, sense, 59-UUC UCC GAA CGU GUC ACG UTT-39, antisense, 59-ACG UGA CAC GUU CGG AGA ATT-39.Statistical AnalysisStudent’s t test and one-way ANOVA were used to analyze the relationship between miR-195 expression and clinicopathologic characteristics. The relationships between Cyclin D1 or Bcl-2 expression and clinicopathologic parameters were explored using the Pearson x2 test. Correlation between miR-195 expression and Cyclin D1 or Bcl-2 protein levels was analyzed using Spearman’s rank correlation ML240 custom synthesis coefficient analysis with r and P values as indicated. Survival curves were constructed by the Kaplan-Meier method and the curves were compared using the log-rank test. The Cox regression model was applied to simultaneously adjust all potential prognostic variables. All statistical analyses were performed using SPSS for Windows version 16.0 (SPSS). Experiments with cell cultures were done at least in triplicate. Data were expressed as mean 6 standard deviation (SD). A twotailed value of P,0.05 was considered to be statistically significant.Results miR-195 Expression was Reduced in TSCC and was Correlated with Cance.Tant 39UTRs. The primers for cloning the mutant 39-UTRs of Cyclin D1 and Bcl-2 were as follows: Cyclin D1 binding site 1, sense, 59- TTT CTT ATT GCG CAC GTA CCG TTG ACT TCC AG-39 and antisense, 59- CTG GAA GTC AAC GGT ACG TGC GCA ATA AGA AA -39; Cyclin D1 binding site 2,sense, 59- CTT TCA CAT TGT TTG GAC CTA TTG GAG GAT CAG -39 and antisense, 59- CTG ATC CTC CAA TAG GTC CAA ACA ATG TGA AAG -39;Bcl-2, sense, 59- GGA ATA TCC AAT CCT GTC GAC CTA TCC TGC CAA-39 and antisense, 59- TTG GCA GGA TAG GTC GAC AGG ATT GGA TAT TCC-39. All constructs were confirmed by DNA sequencing. SCC-15 and CAL27 cells grown in a 48-well plate were co-transfected with 400 ng of either pcDNA3.0 or pcDNA3.0-miR-195, 40 ng of the firefly luciferase reporter plasmid including the 39-UTR of thetarget gene, and 4 ng of pRL-TK, a plasmid expressing rellina luciferase (Promega, Madison, WI)). After 24 h, the dual-luciferase reporter assay was performed 1326631 as reported [27].Western Blot AnalysisCells were lysed in RIPA lysis buffer (50 mM Tris/HCl, pH 8.0, 250 mM NaCl, 1 NP40, 0.5 (w/v) sodium deoxycholate, 0.1 sodium dodecylsulfate). Lysates were sonicated and centrifuged at 12,000 g/min at 4uC for 10 min. Aliquots (50 mg) of the protein extracts were subjected to 12 SDS polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane (Millipore, Billerica, MA). Membranes were incubated ?with primary antibodies at 4C overnight and washed extensively, followed by incubation with horseradish peroxidase-conjugated second antibodies (Zhongshan Goldenbridge, Beijing, China, 1:10,000 dilution) at room temperature for 1 h and detected with ECL kit (Applygen, Beijing, China). The primary antibodies, Cyclin D1 (Santa Cruz Biotechnology, Santa Cruz, CA), Bcl-2 (Cell Signaling Technology, Beverly, MA), and b-actin (Santa Cruz) were diluted 1:1,000 respectively.RNA OligoribonucleotideThe small interfering RNA (siRNA) targeting human Cyclin D1 and Bcl-2 transcripts and siRNA control were purchased from Integrated Biotech Solutions Company (Ibsbio, Shanghai, China). Sequence of these siRNAs were: Cyclin D1 siRNA, sense, 59-CAA GCU CAA GUG GAA CCU GTT-39, antisense, 59-CAG GUUMiR-195 Is a Prognostic Factor for TSCC PatientsCCA CUU GAG CUU GTT-39; Bcl-2 siRNA, sense, 59-GUG AAG UCA ACA UGC CUG CTT-39, antisense, 59-GCA GGC AUG UUG ACU UCA CTT-39; siRNA control, sense, 59-UUC UCC GAA CGU GUC ACG UTT-39, antisense, 59-ACG UGA CAC GUU CGG AGA ATT-39.Statistical AnalysisStudent’s t test and one-way ANOVA were used to analyze the relationship between miR-195 expression and clinicopathologic characteristics. The relationships between Cyclin D1 or Bcl-2 expression and clinicopathologic parameters were explored using the Pearson x2 test. Correlation between miR-195 expression and Cyclin D1 or Bcl-2 protein levels was analyzed using Spearman’s rank correlation coefficient analysis with r and P values as indicated. Survival curves were constructed by the Kaplan-Meier method and the curves were compared using the log-rank test. The Cox regression model was applied to simultaneously adjust all potential prognostic variables. All statistical analyses were performed using SPSS for Windows version 16.0 (SPSS). Experiments with cell cultures were done at least in triplicate. Data were expressed as mean 6 standard deviation (SD). A twotailed value of P,0.05 was considered to be statistically significant.Results miR-195 Expression was Reduced in TSCC and was Correlated with Cance.

Share this post on:

Author: Proteasome inhibitor